The first successful cochlear implant in Latin America after severe aminoglycoside-induced ototoxicity in a Peruvian patient cured of extensively drug-resistant tuberculosis
DOI:
https://doi.org/10.35434/rcmhnaaa.2022.154.1501Keywords:
Tuberculosis, Extensively Drug-Resistant Tuberculosis, Hearing loss, Latin AmericaAbstract
Introduction: Multidrug-resistant tuberculosis is a significant public health problem for which drugs are used with many adverse effects. Among the devastating consequences of these diseases, there is a wide variation in the incidence of ototoxicity and hearing loss in patients with multidrug-resistant and extremely resistant tuberculosis. Cochlear implants may be indicated in patients with unilateral/severe bilateral hearing loss with no benefit from conventional hearing aids, but their use in patients with tuberculosis is rare. Case report: We present the first case of a right unilateral cochlear implant performed on a 34-year-old Peruvian patient who presented profound sensorineural hearing loss of cochlear origin. Conclusion: Cochlear implant surgery is an essential milestone in the treatment of patients with auditory sequelae of tuberculosis treatment. Close monitoring of possible complications of tuberculosis treatment should be strengthened in countries with a high incidence of multidrug-resistant and extremely resistant tuberculosis.
Downloads
Metrics
References
Global tuberculosis report 2022 [Internet]. [citado 3 de diciembre de 2022]. Disponible en: https://www.who.int/publications-detail-redirect/9789240061729
Rahlwes Kathryn C, Dias Beatriz RS, Campos Priscila C, Alvarez-Arguedas S, Shiloh Michael U. Pathogenicity and virulence of Mycobacterium tuberculosis. Virulence. 23 de noviembre de 2022;0(ja):null.
Arnold A, Cooke GS, Kon OM, Dedicoat M, Lipman M, Loyse A, et al. Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. septiembre de 2017;61(9):e02586-16.
Wilson BS, Tucci DL, Merson MH, O’Donoghue GM. Global hearing health care: new findings and perspectives. Lancet Lond Engl. 2 de diciembre de 2017;390(10111):2503-15.
Korhonen V, Kivelä P, Haanperä M, Soini H, Vasankari T. Multidrug-resistant tuberculosis in Finland: treatment outcome and the role of whole-genome sequencing. ERJ Open Res. 28 de noviembre de 2022;8(4):00214-2022.
Mirzayev F, Viney K, Linh NN, Gonzalez-Angulo L, Gegia M, Jaramillo E, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. junio de 2021;57(6):2003300.
Jiang M, Karasawa T, Steyger PS. Aminoglycoside-Induced Cochleotoxicity: A Review. Front Cell Neurosci. 2017;11:308.
Dillard LK, Martinez RX, Perez LL, Fullerton AM, Chadha S, McMahon CM. Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review. J Infect. julio de 2021;83(1):27-36.
Pecho-Silva S. Tratamiento de tuberculosis MDR / XDR en Perú. ¿Vamos por buen camino? Rev Peru Investig En Salud. 19 de junio de 2020;4(3):134-7.
van Altena R, Dijkstra JA, van der Meer ME, Borjas Howard JF, Kosterink JGW, van Soolingen D, et al. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. marzo de 2017;61(3):e01400-16.
Alcas O, Salazar MA. Complications of cochlear implant surgery: A ten-year experience in a referral hospital in Peru, 2006-2015. Cochlear Implants Int. septiembre de 2016;17(5):238-42.
Vaid N, Jana JJ, Kothadiya A, Deshpande S, Vaid S. Bilateral cochlear implantation under local anaesthesia in a young adult - A case report. Cochlear Implants Int. julio de 2016;17(4):207-10.
Chávez Cáceres SR. Estudio epidemiológico del implante coclear en el Perú de 1999 al 2009. 25 de septiembre de 2018 [citado 3 de diciembre de 2022]; Disponible en: https://tesis.pucp.edu.pe/repositorio/handle/20.500.12404/12744
Castañeda-Hernández DM, Tobón-García D, Rodríguez-Morales AJ. Asociación entre incidencia de tuberculosis e Índice de Desarrollo Humano en 165 países del mundo. Rev Peru Med Exp Salud Publica. octubre de 2013;30(4):560-8.
Ortiz-Martínez Y, Mogollón-Vargas JM, López-Rodríguez M, Rodriguez-Morales AJ. A fatal case of triple coinfection: COVID-19, HIV and Tuberculosis. Travel Med Infect Dis. 2021;43:102129.
Ortiz-Martinez Y, Mejia-Alzate C, Vega-Vera A, Fajardo-Rivero JE, Rodriguez-Morales AJ. Drug-resistant tuberculosis and COVID-19 co-infection: A systematic review of case reports. Int J Mycobacteriology. 2021;10(2):214-5.
Ortiz-Martínez Y, Fajardo-Rivero JE, Mendoza-Herrera T, Ruiz-González CE, Masias-León Y, Luna C, et al. Differences in tuberculosis incidence among patients with hematological malignancies and general population, Santander, Colombia, 2015-2019. Int J Mycobacteriology. 2021;10(3):346-8.
Garcia-Solorzano FO, Ramos-Ramirez KE, Heredia-Torres PL, Castañeda-Hernández DM, Rodriguez-Morales AJ. El Niño Southern Oscillation and tuberculosis: Is there an association? J Infect Public Health. 2019;12(2):292-3.
Mantefardo B, Sisay G. Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen. Int Med Case Rep J. 2021;14:815-7.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Samuel Pecho-Silva, Ana Claudia Navarro-Solsol, Vicky Panduro-Correa, Jorge L. Maguina, Ali A. Rabaan, Luis Rene Quiroz-Ramirez, Kovy Arteaga-Livias, Alfonso J. Rodriguez-Morales
This work is licensed under a Creative Commons Attribution 4.0 International License.
